Key Takeaways
- Germany did not pass a new cannabis law, but Hesse’s guidance could reshape the global cannabis supply chain significantly.
- The guidance classifies drying cannabis as a critical GMP step, tightening requirements for quality during importation.
- Hesse’s interpretation challenges the existing supply model, which has relied on GMP washing, as it raises quality standards.
- European producers, especially from Portugal and Denmark, may benefit while Canadian exporters might face higher compliance costs.
- Hesse’s guidance is state-level, not EU-wide, yet it might influence other German states and EU member states in the future.
Germany did not pass a new cannabis law this summer. It did not touch an import quota. Instead, a single state health authority published a guidance document, and that document may end up reshaping the global cannabis supply chain more than any legislation has.
On June 8th, the Hessian State Office for Health and Care (HLfGP) issued a Merkblatt stating that drying cannabis flower under controlled conditions is a critical manufacturing step. That places drying squarely under EU Good Manufacturing Practice (GMP), not the lighter Good Agricultural and Collection Practice (GACP) standard that governs cultivation.
The distinction sounds technical. Its consequences are not. For years, the international cannabis trade has relied on a split model: grow and initially process flower under agricultural rules in Canada or elsewhere, then convert it into a GMP-compliant medicine after it reaches Europe. Hesse just questioned whether that model was ever compliant in the first place.
What Germany’s GMP Interpretation Actually Says
The HLfGP guidance provided by Business of Cannabis, makes three points that matter for anyone shipping flower into Germany.
First, drying is a critical manufacturing step. The authority states that drying under controlled conditions has a decisive influence on product quality, which makes its parameters critical process parameters under GMP. Saying flower “was dried” is no longer enough. Producers now need evidence of how it was dried and within what limits.
Second, the authority says it knows of no process proving that GACP flower can travel long distances, sit in storage, clear import, and then be processed further without losing quality. The logic that follows is hard to dodge. Either the flower loses its GACP status in transit, or it keeps that status but cannot be shown to arrive intact. Either way, the HLfGP concludes that GMP-compliant processing, including drying and trimming, should generally happen where the plants are harvested.
Third, foreign rules do not change the German expectation. If flower is partly manufactured in a country where GMP does not apply, the guidance says GMP still has to be observed for any material released and sold as medicine in Germany.
Responsibility sits with the Qualified Person under Germany’s Medicines Act, the individual who releases each batch for sale. That accountability holds even when steps happen in another EU state or a third country operating under different rules.
The Reprocessing and Microbial Question
The guidance also tightens the treatment of decontamination. Techniques that reduce microbial load, including irradiation, are classified by the HLfGP as reprocessing under Chapter 5, Section 5.67 of the EU GMP guide.
Reprocessing is allowed only in exceptional cases, under strictly defined conditions and a full risk assessment. Where such treatment is applied across most batches, the guidance says it must become part of the validated standard manufacturing process rather than a fix applied after the fact. A batch put through those steps cannot reach the market without proof of suitability and stability.
The document points to Category B of European Pharmacopoeia Section 5.1.8 as the microbiological reference. Experts have flagged a wrinkle here: that section was written for oral products, so applying its limits to inhaled cannabis needs its own justification.
How Did the Supply Chain Get Built This Way?
The economics of European medical cannabis rested on a split for years.
Cultivators in Canada, Portugal, and elsewhere grew flower under GACP, the recognized standard for herbal starting materials. That flower was then shipped to an EU-GMP facility that dried, trimmed, decontaminated, tested, packaged, and released it as a finished medicine. On paper, the finished product carried EU-GMP certification.
In practice, some of the steps that most affect quality, drying and microbial control among them, may have happened before GMP oversight ever began. Critics call the arrangement “GMP washing”: routing agricultural flower through a European facility so it earns a certificate the original material never held at source.
The model worked because it was cheap and fast. Growing under agricultural rules costs far less than building pharmaceutical-grade cultivation. Hesse’s guidance targets exactly that cost advantage.
Who Stands Where?
The real assignment now is a map of where cannabis is cultivated, dried, trimmed, irradiated, tested, and legally turned into medicine. Here is how the major origins line up.
Canada is the most exposed. It remains the single largest supplier to Germany, providing nearly half of imports; Stratcann reported that of the cannabis imported in 2025, roughly 93,000 kg originated in Canada. Much of that volume reached patients through the GACP-at-source, GMP-in-Europe model now under question. Canadian producers built their lead on cost and logistics, not on end-to-end pharmaceutical quality, which is precisely the advantage Hesse’s reading erodes.
Portugal sits in a stronger spot. It is Europe’s main processing hub and a fast-growing exporter in its own right, shipping 66,305 kg in the first half of 2026 alone, over 80% of its full 2025 total, according to Infarmed. Portuguese producers with European pharmaceutical infrastructure are positioned to absorb work that can no longer be split across an ocean.
Denmark looks similarly placed. As an EU producer with GMP-aligned facilities, it stands to benefit from any shift toward sourcing inside Europe’s own regulatory bloc.
South Africa and Latin America face the steepest climb. Lower-cost producers in these regions could still capture share as more origins qualify, but higher compliance costs favor larger operators. Producers that treated cannabis as an agricultural business, in Prohibition Partners CEO Stephen Murphy’s words via MjBizDaily, “are the most exposed.”
What Happens If It Spreads Beyond Hesse?
Hesse is Germany’s fifth-largest state by population, but its reach may not stop at its own border.
German pharmaceutical supervision is decentralized. Each federal state runs its own inspections and can adopt its own interpretation. According to reporting, districts including Darmstadt and Cologne have already moved against GMP washing. Legal experts believe authorities have strong connections, and others are likely to follow the same approach.
The reach could extend past Germany too. The underlying legal basis is EU Directive 2001/83/EC, which makes GMP mandatory for manufacturing medicinal products. That means competent authorities in other member states could bring equivalent challenges. As Murphy put it, “If GMP obligations move upstream to the point of cultivation, the entire sourcing map changes.”
One Caveat Worth Keeping in View
We want to be precise about what this is, and what it is not.
Hesse’s guidance is a state-level interpretation, not a binding EU-wide rule. Treating it as one would overstate the development. The Merkblatt is an information sheet describing how one authority reads existing regulations, and Germany still struggles to reject some multi-country supply chains outright.
That said, “interpretation” and “toothless” are not the same thing. Niermann was blunt that there is “no right to GMP washing” and that operators cannot easily contest the reading in court. A guidance document that reflects the current legal position can shape behavior long before any new law arrives.
Where Does Manufacturing Begin?
Strip away the acronyms and one question sits at the center of all of this. Where does farming end and pharmaceutical manufacturing begin?
For a decade, the industry answered that question generously, drawing the line late enough that most quality-defining work could happen under cheaper agricultural rules. Hesse just drew the line earlier, at the point of drying.
Moving GMP responsibility closer to cultivation carries real consequences for foreign producers. They may need to renovate facilities, obtain additional certification, rewrite quality agreements with European partners, or, in some cases, walk away from the German market entirely. Producers with European pharmaceutical infrastructure gain ground. Those built for agricultural volume lose it.
Where This Leaves the Market
Germany remains the gravitational center of global medical cannabis, and nothing in this guidance changes that demand. What it changes is the sourcing architecture underneath it.
Canada holds the near-term lead on volume, infrastructure, and reliability. Whether it holds that lead through 2028 will depend on whether its producers can prove genuine end-to-end pharmaceutical quality rather than lean on the cost and logistics edge that built their position. Expect more intra-European trade as Danish and Portuguese capacity expands, and expect compliance costs to keep rising for everyone outside the bloc.
The smart move for any exporter is not to wait for enforcement. Map your supply chain against the new drying and processing expectations, and figure out where your quality is actually built. The producers who can answer that question with evidence will still be shipping when GMP washing runs out of road.
Frequently Asked Questions
The Hessian State Office for Health and Care (HLfGP) has issued new guidance that reclassifies cannabis flower drying as a critical GMP step, tightens rules around microbial reduction, and requires import applications to clearly outline which facility performed each production step under GACP or GMP standards.
GMP washing is when cannabis flower grown under basic agricultural standards is processed through an EU-GMP facility to obtain a GMP certificate that the original material didn’t qualify for. Germany’s Hesse interpretation holds that this process does not create compliance that wasn’t there from the beginning.
Canada supplies more medical cannabis flower to Germany than any other country, but cost and logistics — not pharmaceutical quality — have driven its competitive edge.. A new rule from Hesse that raises quality standards for imported, third-party-processed flower could therefore hit Canadian exports the hardest.
European producers, particularly those in Portugal and Denmark, are likely to benefit from new regulations that keep pharmaceutical work within Europe. Meanwhile, exporters from Canada, South Africa, and Latin America may face increased compliance costs as a result.
Hesse’s guidance is not an EU-wide rule, but rather a state-level interpretation of existing regulations. That said, other German states may follow suit, and since EU Directive 2001/83/EC underpins the guidance, other EU member states could raise similar challenges.
